The Series
One deal per post.
What happened next.
$535M promised for a Chinese lung cancer drug. $25M documented.Post 01Hansoh → EQRx, 2020. Terminated in 2023.Read the carousel (PDF)See the deal in the terminal
$535M promised for a Chinese lung cancer drug. $25M documented.Post 02Hansoh → EQRx, 2020. Terminated in 2023.Read the carousel (PDF)See the deal in the terminal
$535M promised for a Chinese lung cancer drug. $25M documented.Post 03Hansoh → EQRx, 2020. Terminated in 2023.Read the carousel (PDF)See the deal in the terminal
$535M promised for a Chinese lung cancer drug. $25M documented.Post 04Hansoh → EQRx, 2020. Terminated in 2023.Read the carousel (PDF)See the deal in the terminal
$535M promised for a Chinese lung cancer drug. $25M documented.Post 05Hansoh → EQRx, 2020. Terminated in 2023.Read the carousel (PDF)See the deal in the terminal
$535M promised for a Chinese lung cancer drug. $25M documented.Post 06Hansoh → EQRx, 2020. Terminated in 2023.Read the carousel (PDF)See the deal in the terminal
$535M promised for a Chinese lung cancer drug. $25M documented.Post 07Hansoh → EQRx, 2020. Terminated in 2023.Read the carousel (PDF)See the deal in the terminal
$535M promised for a Chinese lung cancer drug. $25M documented.Post 08Hansoh → EQRx, 2020. Terminated in 2023.Read the carousel (PDF)See the deal in the terminal
$535M promised for a Chinese lung cancer drug. $25M documented.Post 09Hansoh → EQRx, 2020. Terminated in 2023.Read the carousel (PDF)See the deal in the terminal
$535M promised for a Chinese lung cancer drug. $25M documented.Post 10Hansoh → EQRx, 2020. Terminated in 2023.Read the carousel (PDF)See the deal in the terminal
Layout preview: the same post is shown ten times.
The Terminal
The headline number
is a promise.
When a Chinese biotech licenses a drug to a Western buyer, the press release leads with one figure in the billions. Most of it is conditional. The terminal follows each deal after the signature: payments confirmed by a public source, trials started, programmes dropped, rights returned. A date slider rewinds every deal to what was public on that day.
- 50
- deals tracked
- $126.4B
- announced
- $3.6B
- confirmed paid in public sources
- 12
- ended or cut back
Figures pending review
Method
How the numbers
are built.
- Announced
- The upfront plus every milestone the announcement mentions. It is the ceiling of the deal, reached only if every trial, filing and sales target succeeds.
- Confirmed paid
- Payments that a public document says were made or received: a regulatory filing, a stock-exchange announcement, a company release. Without such a document the deal shows n/d, never zero.
- Status
- Active, partly returned or terminated. It is read from the dated events of each deal: a termination, rights handed back, a programme dropped.
- As of
- The terminal can rewind to any month. An event counts from the date of the source that reports it, so a payment made in 2021 and disclosed in a 2023 filing appears in 2023.
- Sources
- Public documents only. Filings, company releases and trial registries come first; trade press is used as a secondary source and labelled as such.
- Limits
- Each deal is entered by hand, one file per deal. The files are still waiting for a second review, so figures may change. This is descriptive research, not investment advice.